Recro Pharma Inc. (REPH): Facts to know about REPH?

0
44

Recro Pharma Inc. (NASDAQ:REPH) changes shares on Friday trading session, with a change of -2.07% or -$0.1 shares. The trading starts at $4.89 and closed at $4.83 throughout the day. The trading session low price was $4.69 and day high was $4.95 on Friday, June 19. After the session, the Healthcare sector daily volume shifted to 0.41 million while its average volume is 588.37K. In other hand, the REPH market cap reached to $110.07M. While, its current target price is $4.73 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -3.86% and up 2.16% for month. Its quarterly performance was -31.55% below, while its half year performance is down -72.01%. REPH yearly performance stood at negative -46.59% and fall -74.20% for year-to-date. Current recommendation for Recro Pharma Inc. is 1.00.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. REPH EPS (TTM) for 12-month is -0.05. EPS for this year is 105.30%, while for the next year its value is 0.43. It has an EPS of 15.70% up for past five years.

Let’s take a look on the analyst recommendations on REPH for the current month and previous month. For the current month, 2 of 2 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $9.00-$12.00. Average target price for REPH was reached at $10.50.

Blackrock Inc., Renaissance Technologies, LLC and Engine Capital Management, LP are the top three holders in Recro Pharma Inc. (REPH) stock. On Mar 30, 2020, Blackrock Inc. has 1.34 million shares which valued 10.96 million. On Mar 30, 2020, Renaissance Technologies, LLC owned 1.23 million shares which valued at 10.06 million. On Mar 30, 2020, Engine Capital Management, LP has a total of 1.1 million shares which valued at 9.02 million. In the end, Engine Capital Management, LP have 4.69% shares outstanding of Recro Pharma Inc. (REPH) on Mar 30, 2020. The insider ownership moved to 2.50% and institutional holding shifted to 78.50%.

The company posted an EPS (TTM) of -0.05. According to the most recent quarter report on (Jun 2020), 2 analysts estimated an average EPS of -0.16, while -0.13 EPS posted a year ago period. Analyst Estimated EPS for REPH published in the report was -0.2–0.12 during the same period. Comparing with last year, the average estimated EPS was -0.13 which is higher than -0.33 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for REPH fall -59.44% for period of 200 days. SMA for 50 days was -25.00% which is showing red signal, while SMA-20 was -3.37%. The moving average value for Recro Pharma Inc. (REPH) is 11.3324 and 5.3874 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in REPH stock. On Apr 17, HENWOOD GERALDINE, President and CEO, sold 80,000 trading shares at the cost of $8.22, which valued at 0.66 million.